Gimeno
Antonio Eduardo Palomares Gimeno, Valencia ES
Patent application number | Description | Published |
---|---|---|
20080302736 | BIMETALLIC CATALYST FOR THE TREATMENT OF WATER CONTAINING NITRATES - A catalyst which, by means of a reduction reaction at ambient temperature, permits the elimination of nitrates and nitrites in waters. The catalyst comprises a combination of a noble metal and a non-noble metal supported on or incorporated into the structure of a support which, in elemental and anhydrous form, has the formula XYMgAl, in which X is at least one noble metal, Y is at least one non-noble metal, Mg is magnesium and Al is aluminium, the Mg and Al preferably forming the structure of a hydrotalcite or a mixed oxide deriving from a hydrotalcite. | 12-11-2008 |
20150118134 | METHOD AND SYSTEM FOR THE PURIFICATION OF EXHAUST GAS FROM AN INTERNAL COMBUSTION ENGINE - The invention provides a method and system for the purification of exhaust gas from an internal combustion engine, comprising a filter and a SCR catalyst. The filter is periodically regenerated increasing the temperature of the exhaust gas up to 850° C. and the water vapour content up to 100% by volume. The SCR catalyst comprises a hydrothermally microporous stable zeolite and/or zeotype having the AEI type framework and being promoted with copper. | 04-30-2015 |
Carmelo Gimeno, Aarau CH
Patent application number | Description | Published |
---|---|---|
20090120909 | Grounding Disconnector and a Method of Manufacturing Such a Grounding Disconnector - Assembly for a grounding disconnector, said assembly comprising a stationary grounding contact ( | 05-14-2009 |
Eduardo Tortosa Gimeno, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20080269384 | Polyphosphate Derivative of a 1,3,5-Triazine Compound, Method for Producing the Same and its Use - Phosphate derivatives of a 1,3,5-triazine compound, preferably melamine polyphosphate, which are heat-resistant at the processing temperature, are selected which have an average condensation coefficient n (number average)>20, a pH-value of a 10% slurry of the polyphosphate derivative in water at 25° C. of 5 or higher, a molar ratio of 1,3,5-triazine compound to phosphorus (M/P)<1.1 and a decomposition temperature >320° C. They can be produced by heat treatment of an orthophosphate or condensed phosphate with an average condensation coefficient n (number average) below 20 in an ammonia atmosphere at a temperature in the range of 300 to 400° C. until the average condensation coefficient is above 20 and the molar ratio of 1,3,5-triazine compound to phosphorus (M/P) is below 1.1. The polyphosphates of the invention can be represented in simplified form by the following general formula: | 10-30-2008 |
Maria Conception Gimeno, Zaragoza ES
Patent application number | Description | Published |
---|---|---|
20130066092 | USE OF GOLD COMPLEXES IN OPTOELECTRONIC DEVICES - The invention relates to gold(I) complexes having a planar-trigonal coordination geometry and multivalent ligands for use in an optoelectronic device, in particular in organic light-emitting diodes (OLEDs) and in light-emitting electrochemical cells (LEECs). | 03-14-2013 |
Patricia Gimeno, Stuttgart DE
Patent application number | Description | Published |
---|---|---|
20160075600 | FAST CURING COMPOSITION FOR THE MANUFACTURE OF POLYURETHANE CEMENTITIOUS HYBRID FLOORING - The present application relates to a multi-component composition comprising a polyol component comprising one or more polyols and water, a polyisocyanate component comprising methylene diphenyl diisocyanate (MDI), a powder component comprising cement, calcium hydroxide and one or more aggregates and less than 0.5 wt.-%, based on the total weight of the polyol, polyisocyanate and the powder component, of a curing accelerator component comprising an amino alcohol and an acid. Polyurethane cementitious hybrid flooring or coating systems having an improved curing speed and enhanced aesthetic properties in that they show substantially no difference in colour shade can be achieved. Blister formation can be avoided. | 03-17-2016 |
Robert Gimeno, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20160063419 | INVENTORY OPTIMIZATION TOOL - This disclosure generally relates to devices, systems, and computer-implemented methods for simulating one or more inventories in a distribution network. Specifically, methods are described that comprise the operations of receiving inventory data for one or more inventories to be simulated, wherein the inventory data includes lead time data and demand data; determining, based on the inventory data, probability distributions for each of lead time and demand for the one or more inventories to be simulated; determining a lead time demand probability distribution of the one or more inventories to be simulated based on the determined probability distributions for the lead time and the demand; determining a predictive state of the one or more inventories to be simulated based on the lead time demand probability distribution; and outputting one or more evaluation parameters associated with the predictive state of the one or more inventories to be simulated. | 03-03-2016 |
Ruth Gimeno, Wellesley, MA US
Patent application number | Description | Published |
---|---|---|
20100092941 | 32142,21481,25964,21686, Novel dehydrogenase molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 04-15-2010 |
Ruth E. Gimeno, Wellesley, MA US
Patent application number | Description | Published |
---|---|---|
20080241129 | ADIPOCYTE SECRETED PROTEIN CCDC80 IS A POTENT STIMULATOR OF BONE FORMATION - Disclosed herein are methods of using Ccdc80, Ccdc80 mimics, or Ccdc80 agonists or antagonists in the treatment of bone disorders. | 10-02-2008 |
20090269332 | Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 10-29-2009 |
20100035339 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 02-11-2010 |
20120003233 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 01-05-2012 |
20120177661 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 07-12-2012 |
20130078239 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 03-28-2013 |
20140010799 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 01-09-2014 |
Ruth Elisabeth Gimeno, Wellesley, MA US
Patent application number | Description | Published |
---|---|---|
20080221057 | SECRETED PROTEIN CCDC80 REGULATES ADIPOCYTE DIFFERENTIATION - Disclosed herein are methods of modulating adipogenesis. The methods include contacting a cell expressing the Ccdc80 gene with an agent that modulates the expression or activity of the Ccdc80 gene or Ccdc80 protein. Further disclosed herein are methods of treating conditions such as obesity, insulin resistance, and/or type 2 diabetes with Ccdc80 modulators. Also disclosed herein are methods of identifying Ccdc80 modulators. | 09-11-2008 |